Health Care

Insider sale by NIGON RICHARD in bullish Celcuity stock: a tactical rebalancing, not a red flag—watch derivative‑to‑equity moves and clinical pipeline for insights.

Insider buying surge at SELLAS Life Sciences: over 900,000 shares bought by senior execs signals confidence, yet market sentiment lags—watch FDA milestones and earnings for a potential rally.

Insider selling spurs debate: Acumen execs liquidate shares amid volatility, yet 10b5‑1 plans and a 52‑week low hint at a value play for cautious investors.

Chacon Quiros Juan Jose’s August 2025 share purchase and new equity award at Establishment Labs signals insider confidence amid price‑earnings concerns and a 52‑week low, urging investors to weigh long‑term gains against current risks.

Arcus insider selling: CEO Terry Rosen’s recent “charitable gift” stock sale signals cautious portfolio shifts and impacts investor sentiment on the biotech’s future.

Neumora’s insiders buy 4.5 M shares of stock‑options, signaling confidence in its brain‑therapy pipeline and a bullish outlook for the neuro‑pharma sector.

Insight into COO Margaret Horn’s 10b5‑1 trades at Revolution Medicines and what it means for investors and the company’s future.

Vericel insider trades reveal a disciplined buy‑sell‑exercise pattern, boosting confidence in the COO’s long‑term belief in the company’s regenerative‑medicine growth.

Altimmune insider buying surges as CEO‑elect Pisano Wayne buys 5,000 shares near a 52‑week low, backing the company’s FDA Breakthrough Therapy designation and promising clinical‑stage growth.

Vertex insider sells 4,500 shares in routine plan‑based trade; market stays bullish on VRTX’s pipeline and earnings outlook.